- Home
- XGN
XGN
Exagen Inc.
as of 01-02-2026 10:13am EST
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | VISTA |
| Market Cap: | 138.9M | IPO Year: | 2019 |
| Target Price: | $13.67 | AVG Volume (30 days): | 295.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.67 - $12.23 | Next Earning Date: | 11-04-2025 |
| Revenue: | $63,599,000 | Revenue Growth: | 14.08% |
| Revenue Growth (this year): | 21.76% | Revenue Growth (next year): | 15.63% |
AI-Powered XGN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Exagen Inc. (XGN)
President and CEO
Avg Cost/Share
$11.82
Shares
31,787
Total Value
$375,598.37
Owned After
714,427
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ABALLI JOHN | XGN | President and CEO | Oct 16, 2025 | Sell | $11.82 | 31,787 | $375,598.37 | 714,427 |
Compare XGN vs Leading Stocks
See how XGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XGN Exagen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.